The allylamines are synthetic antifungal agents with a mechanism of action that is distinct from both the azoles and the echinocandins: they inhibit squalene epoxidase, an enzyme in the fungal ergosterol biosynthesis pathway that precedes the lanosterol demethylation step targeted by azoles. This earlier blockade produces a dual toxic effect and confers antifungal activity that is fungicidal against dermatophytes, the primary clinical target of the class.
Mechanism of Action. Squalene epoxidase (also called squalene monooxygenase) catalyzes the conversion of squalene to 2,3-oxidosqualene (squalene epoxide), an early step in the ergosterol biosynthesis pathway. Terbinafine and naftifine inhibit this enzyme non-competitively and selectively in fungi; the selectivity arises because the fungal enzyme has approximately 10,000-fold greater sensitivity to allylamine inhibition than the mammalian homolog, which accounts for the favorable systemic tolerability of terbinafine at therapeutic doses. Inhibition of squalene epoxidase produces two simultaneous consequences: depletion of ergosterol downstream of the block, which disrupts membrane integrity, and accumulation of squalene upstream of the block, which is directly toxic to the fungal cell. This dual mechanism is responsible for the fungicidal rather than fungistatic activity observed against dermatophytes and distinguishes allylamines mechanistically from azoles, which are only fungistatic against most fungi.1
Terbinafine Pharmacokinetics. Terbinafine is a highly lipophilic compound with oral bioavailability of approximately 40% following first-pass hepatic metabolism. Despite this moderate oral bioavailability, it achieves very high concentrations in skin, nail, and hair tissue because of its lipophilicity and affinity for keratinized structures, producing a tissue-to-plasma concentration ratio that greatly exceeds unity in these compartments. The plasma half-life is approximately 17 hours following a single dose, but the effective tissue half-life in nails and skin is substantially longer because of slow redistribution from these deep compartments back into plasma. The result is that terbinafine persists in nail tissue for weeks to months after the completion of a standard treatment course, providing continued antifungal activity during the slow outgrowth of the newly fungus-free nail plate. Plasma protein binding is greater than 99%, primarily to albumin and lipoproteins.2
Metabolism and Elimination. Terbinafine is extensively metabolized in the liver by multiple cytochrome P450 (CYP) isoforms including CYP2C9 (cytochrome P450 2C9), CYP1A2 (cytochrome P450 1A2), CYP3A4 (cytochrome P450 3A4), and CYP2C8 (cytochrome P450 2C8), with CYP2C9 being the predominant pathway. The resulting metabolites are pharmacologically inactive and are excreted primarily in urine (approximately 70%) with the remainder in feces. Dose adjustment is required for significant hepatic impairment, and terbinafine is generally avoided in patients with Child-Pugh class C cirrhosis. Renal impairment (creatinine clearance (CrCl) below 50 mL/min) also reduces clearance of terbinafine metabolites, and dose reduction to 50% of standard is recommended below this threshold; some authorities recommend avoiding the drug in severe renal impairment. While terbinafine is metabolized by CYP enzymes, it has a relatively modest CYP interaction profile as a victim drug; however, it is a potent inhibitor of CYP2D6 (cytochrome P450 2D6), which has important implications for co-administered drugs metabolized by this isoform.2
Target: squalene epoxidase (earlier in ergosterol pathway than azoles). Dual effect: squalene accumulation (directly toxic) + ergosterol depletion (membrane disruption). Selectivity: fungal enzyme ~10,000-fold more sensitive than mammalian homolog. Activity: fungicidal against dermatophytes; fungistatic against Candida and most yeasts. Tissue accumulation in keratin structures: basis for prolonged post-treatment nail activity.
Terbinafine is the oral allylamine of clinical importance and is the preferred systemic agent for dermatophyte onychomycosis in most current guidelines. Its clinical profile is distinguished by high cure rates in nail disease, a favorable tolerability profile in the great majority of patients, and a small but clinically significant risk of hepatotoxicity requiring monitoring in selected populations.
Indications and Efficacy. The primary indication for oral terbinafine is dermatophyte onychomycosis (fungal nail infection), where it achieves mycological cure rates of approximately 70 to 80% with standard regimens. The standard adult dosing for onychomycosis is 250 mg orally once daily for 6 weeks (fingernails) or 12 weeks (toenails), taking advantage of the prolonged nail tissue concentrations that persist after treatment completion. Terbinafine is also effective for tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete's foot), and tinea capitis (scalp ringworm), though topical formulations are preferred for superficial skin infections when feasible. For tinea capitis caused by Trichophyton tonsurans, oral terbinafine is highly effective and is a preferred alternative to griseofulvin in most current pediatric guidelines. Terbinafine has limited activity against Candida species, Malassezia, and non-dermatophyte molds, which constrains its use to dermatophyte-confirmed infections.23
CYP2D6 (Cytochrome P450 2D6) Inhibition. The most pharmacokinetically consequential drug interaction of terbinafine is its potent inhibition of CYP2D6. This isoform metabolizes a broad range of clinically important drugs including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and paroxetine, certain antipsychotics (haloperidol, risperidone, thioridazine), beta-blockers (metoprolol, timolol), codeine (which requires CYP2D6 for conversion to morphine), and tramadol. When terbinafine is co-administered with a CYP2D6 substrate with a narrow therapeutic index, plasma concentrations of the substrate drug may rise to toxic levels. The interaction is of particular concern in patients taking antidepressants or antipsychotics for whom small concentration increases can produce significant adverse effects. Codeine conversion to morphine is reduced by CYP2D6 inhibition, which may decrease analgesic efficacy in patients relying on this pathway. CYP2D6 inhibition by terbinafine is irreversible (mechanism-based), and its effect persists for weeks after terbinafine discontinuation as new enzyme is synthesized.3
Hepatotoxicity and Monitoring. Terbinafine carries a rare but documented risk of serious hepatotoxicity, including cases of symptomatic hepatitis, cholestatic jaundice, hepatic failure, and death. The estimated incidence of serious liver injury is approximately 1 in 50,000 to 1 in 120,000 treated patients, making it uncommon but important given the large population treated for onychomycosis. Liver function test (LFT) elevations are more common and usually asymptomatic. The mechanism appears to involve idiosyncratic immune-mediated injury rather than dose-dependent hepatocellular damage, which is why it cannot be reliably predicted by monitoring alone. Current prescribing guidance recommends obtaining baseline LFTs before starting terbinafine in patients with pre-existing liver disease or significant alcohol use, and discontinuing the drug if alanine aminotransferase (ALT) or aspartate aminotransferase (AST) rises to more than three times the upper limit of normal (ULN) with symptoms or five times ULN asymptomatically. Patients should be counseled to report jaundice, dark urine, or right upper quadrant discomfort promptly.3
CYP2D6 inhibition: potent, mechanism-based (irreversible), persists weeks after stopping. High-risk combinations: TCAs, certain antipsychotics, metoprolol, codeine. Hepatotoxicity: rare but serious; obtain baseline LFTs in high-risk patients; stop if ALT/AST above 3×ULN with symptoms or 5×ULN without. Renal dose adjustment: reduce 50% if CrCl below 50 mL/min; avoid in severe renal impairment. Limited Candida activity: confirm dermatophyte etiology before prescribing for nail disease.
Flucytosine (5-fluorocytosine, 5-FC) is a synthetic fluorinated pyrimidine with a unique mechanism of action among antifungal agents: it acts as an antimetabolite, disrupting both RNA (ribonucleic acid) synthesis and DNA (deoxyribonucleic acid) synthesis after intracellular conversion to active metabolites. It is not used as monotherapy because resistance develops rapidly, but it remains clinically important as a synergistic partner in the treatment of cryptococcal meningitis and selected other severe fungal infections.
Mechanism of Action. Flucytosine enters fungal cells via the permease enzyme cytosine permease, which actively transports it across the fungal cell membrane. Inside the cell, it is converted to 5-fluorouracil (5-FU) by cytosine deaminase, an enzyme present in fungi (and some bacteria) but essentially absent in mammalian cells; this selectivity of intracellular conversion is the basis for the drug's selective fungal toxicity. 5-FU is then further metabolized via two pathways: it is converted to fluorodeoxyuridine monophosphate (FdUMP), which inhibits thymidylate synthase and thereby blocks DNA synthesis, and it is incorporated into RNA as fluorouridine triphosphate (FUTP), disrupting protein synthesis. This dual disruption of both DNA and RNA synthesis contributes to the drug's antifungal effect. The selectivity of cytosine deaminase for fungal (and not mammalian) cells means that systemic 5-FU generation is limited in the absence of intestinal bacterial conversion, preserving tolerability at standard doses.4
Pharmacokinetics. Flucytosine is well absorbed orally with bioavailability exceeding 90%, making the oral and intravenous (IV) routes essentially interchangeable pharmacokinetically. It is minimally protein-bound (approximately 4%), widely distributed, and penetrates excellently into the cerebrospinal fluid (CSF), achieving CSF concentrations that are 70 to 85% of concurrent plasma concentrations; this CSF penetration is a major reason for its use in cryptococcal meningitis, where adequate CSF drug levels are essential. The volume of distribution approximates total body water (approximately 0.6 liters per kilogram (L/kg)), reflecting its hydrophilic character. Flucytosine is eliminated almost entirely by renal excretion of unchanged drug; more than 90% of a dose appears in urine as intact flucytosine. This near-exclusive renal elimination means that dose adjustment is mandatory in renal impairment, and the drug requires careful monitoring in any patient with changing renal function.45
Toxicity and Narrow Therapeutic Index. The principal dose-limiting toxicities of flucytosine are hematologic: leukopenia, thrombocytopenia, and anemia, collectively termed myelosuppression. These arise because intestinal bacteria convert flucytosine to 5-FU in the gut, producing systemic 5-FU exposure that suppresses bone marrow at high drug concentrations. The risk of myelosuppression is concentration-dependent and rises sharply when flucytosine trough concentrations exceed 100 mg/L; the lower target of 25 to 50 mg/L at two hours post-dose (peak) provides efficacy while limiting toxicity. Hepatotoxicity with elevation of transaminases and alkaline phosphatase occurs in 5 to 10% of patients and is generally reversible with dose reduction or discontinuation. Because both toxicities are concentration-dependent, therapeutic drug monitoring (TDM) is mandatory for all patients receiving flucytosine, particularly those with impaired or fluctuating renal function, neonates, and patients receiving concurrent nephrotoxins such as amphotericin B.5
Renal Dose Adjustment. Because flucytosine is renally cleared, dosing must be adjusted based on CrCl (creatinine clearance). The standard dose is 25 mg/kg orally or IV every 6 hours (100 mg/kg/day in four divided doses). For CrCl of 25 to 50 mL/min, the dosing interval is extended to every 12 hours (50 mg/kg twice daily). For CrCl of 13 to 25 mL/min, the interval is extended to every 24 hours. Below CrCl of 13 mL/min, or in patients on hemodialysis, flucytosine should be given as a single dose of 25 mg/kg after each dialysis session, with TDM guiding subsequent dosing. In patients with acute kidney injury whose renal function is changing rapidly, TDM is the primary guide to dosing rather than fixed creatinine-based tables, because measured concentrations reflect actual drug exposure more accurately than estimated clearance calculations.5
Target 2-hour post-dose (peak) concentration: 25–50 mg/L (some protocols use 40–60 mg/L for CSF infections). Toxic threshold: trough above 100 mg/L → myelosuppression risk increases sharply. Monitor CBC (complete blood count) twice weekly during therapy; LFTs weekly. Renal function monitoring mandatory: flucytosine clearance tracks GFR directly. Concurrent amphotericin B reduces renal clearance of flucytosine → reduces dosing interval or dose when AmB added.
Flucytosine is never used as monotherapy for serious infections because primary resistance is common among Candida species and secondary (acquired) resistance develops rapidly when it is used alone against susceptible organisms. Its clinical value lies entirely in synergistic combination regimens, where it contributes antifungal activity and reduces the likelihood of resistance emergence.
Synergy with Amphotericin B. The combination of amphotericin B (AmB) with flucytosine is the standard induction regimen for cryptococcal meningitis and represents one of the most well-established synergistic antifungal combinations in clinical medicine. The mechanistic basis for synergy is that amphotericin B, by disrupting the fungal cell membrane through ergosterol binding, increases the permeability of the membrane to flucytosine, enhancing its intracellular uptake and thereby potentiating its antimetabolite effect at concentrations that would be insufficient alone. Clinical evidence from randomized trials, including the foundational ACTA (Advancing Cryptococcal Meningitis Treatment for Africa) trial conducted in sub-Saharan Africa and studies in high-income settings, demonstrates that one week of induction therapy with amphotericin B plus flucytosine achieves superior early fungicidal activity and improved survival compared to amphotericin B monotherapy or fluconazole-based regimens. The World Health Organization (WHO) 2022 guidelines for cryptococcal disease recommend amphotericin B plus flucytosine as the preferred induction regimen where both drugs are available.7
Synergy with Fluconazole. When amphotericin B is unavailable or contraindicated, combination of flucytosine with fluconazole is the recommended alternative induction regimen for cryptococcal meningitis. The ACTA trial demonstrated that this oral combination achieved faster CSF (cerebrospinal fluid) sterilization and reduced 10-week mortality compared to fluconazole monotherapy, establishing it as an accessible alternative for resource-limited settings where IV amphotericin B cannot be administered. The recommended doses in this regimen are fluconazole 1200 mg orally once daily plus flucytosine 25 mg/kg orally four times daily for two weeks of induction, followed by consolidation with fluconazole. The combination is pharmacologically rational because fluconazole impairs ergosterol synthesis (indirectly enhancing flucytosine uptake) while flucytosine adds a complementary mechanism targeting nucleic acid synthesis.7
Resistance Mechanisms. Primary resistance to flucytosine among Candida species is common, particularly in C. krusei (now reclassified as Pichia kudriavzevii), which is intrinsically resistant, and in C. glabrata, where resistance rates are variable and institution-dependent. Resistance arises through mutations in three steps of the flucytosine activation pathway: loss-of-function mutations in the gene encoding cytosine permease (UPT1 and FCY2), which prevent intracellular drug transport; loss-of-function mutations in cytosine deaminase (FCY1), which prevent conversion to 5-FU; and mutations in URA3 (orotidine-5-phosphate decarboxylase gene) or URA5 (orotate phosphoribosyltransferase gene), encoding enzymes in the downstream phosphorylation pathway that converts 5-FU to active nucleotides. Secondary resistance during therapy develops rapidly when flucytosine is used as monotherapy; resistance can emerge within days of initiating single-agent therapy against a susceptible isolate. Co-administration with amphotericin B appears to reduce secondary resistance emergence by reducing the fungal burden faster, limiting the probability of selecting resistant mutants from the population.45
Never use as monotherapy: resistance emerges rapidly. Preferred combination for cryptococcal meningitis induction: amphotericin B (preferably liposomal) + flucytosine for 1–2 weeks (WHO 2022 preferred regimen). Alternative where IV AmB unavailable: fluconazole 1200 mg + flucytosine 25 mg/kg q6h × 2 weeks (ACTA trial). Mandatory TDM for all patients. C. krusei: intrinsically resistant. Check susceptibility before use in C. glabrata. Also used as synergistic partner in selected cases of Candida meningitis and endophthalmitis.
Griseofulvin is a natural product derived from Penicillium griseofulvum with antifungal activity that is mechanistically unique: it disrupts fungal mitosis by binding to tubulin and inhibiting microtubule polymerization, rather than targeting ergosterol biosynthesis or cell wall synthesis. Its clinical use has substantially narrowed since the introduction of terbinafine and itraconazole, but it retains an important role in tinea capitis in pediatric patients, where it is an inexpensive and well-studied option.
Mechanism of Action. Griseofulvin binds to tubulin monomers and inhibits their polymerization into microtubules, disrupting the mitotic spindle apparatus required for nuclear division. This produces multinucleated, abnormally shaped fungal cells that are unable to complete cell division, ultimately leading to cell death. Because microtubules are present in mammalian cells as well, selectivity is not based on target absence (as with echinocandins targeting beta-glucan) but rather on differential uptake: griseofulvin is actively concentrated within fungal cells and in keratinized tissues. The drug is deposited in newly synthesized keratin precursor cells and accumulates in skin, hair, and nail as these structures grow outward, where it inhibits dermatophyte invasion of newly formed keratin. Its activity spectrum is limited to dermatophytes; it has no meaningful activity against Candida, Aspergillus, Cryptococcus, or the Mucorales.8
Pharmacokinetics and Formulations. Griseofulvin is available in two oral formulations: microsize (Griseofulvin V) and ultramicrosize (Gris-PEG), which differ in particle size and thereby in oral absorption. Microsize griseofulvin has bioavailability of approximately 25 to 70% depending on fat content of co-administered food; absorption is significantly enhanced when taken with a high-fat meal, and patients are routinely instructed to take it with fatty food. Ultramicrosize formulation is more consistently and completely absorbed (bioavailability approximately 70%) and can be given at a lower absolute dose (typically 375 mg once daily ultramicrosize vs. 500 mg once daily microsize for tinea capitis in adults). The drug is widely distributed after absorption, with selective accumulation in sweat, skin surface lipids, and newly forming keratin. The plasma half-life is approximately 9 to 24 hours, requiring once- or twice-daily dosing. Griseofulvin is metabolized in the liver primarily by CYP3A4 (cytochrome P450 3A4) to the inactive metabolite 6-demethylgriseofulvin, with approximately 1% excreted unchanged in urine.89
Drug Interactions and Contraindications. Griseofulvin is an inducer of CYP3A4 and CYP1A2 (cytochrome P450 1A2), which reduces plasma concentrations of several co-administered drugs. The most clinically important interactions involve oral contraceptives (OCs): griseofulvin reduces plasma concentrations of ethinylestradiol, potentially causing contraceptive failure; patients of childbearing potential must be counseled to use a barrier method during and for one month after completing griseofulvin treatment. Warfarin anticoagulation is reduced by griseofulvin-induced CYP (cytochrome P450) enzyme induction, requiring INR (international normalized ratio) monitoring and possible warfarin dose increase during co-administration. Cyclosporine plasma levels may be reduced. Alcohol combined with griseofulvin produces a disulfiram-like reaction (flushing, tachycardia, nausea) in some patients and should be avoided during therapy. Griseofulvin is teratogenic in animal studies and is contraindicated in pregnancy; it is also contraindicated in patients with hepatocellular failure or porphyria (it induces porphyrin synthesis).9
Clinical Indications and Duration. The principal current indication for griseofulvin is tinea capitis caused by Microsporum and Trichophyton species, particularly in children for whom it has the longest safety record and regulatory approval in many jurisdictions. Standard pediatric dosing for tinea capitis is 20 to 25 mg/kg/day for microsize or 10 to 15 mg/kg/day for ultramicrosize formulation, taken with fatty food, for a minimum of 6 to 8 weeks. Treatment duration must be sufficient to allow replacement of the infected keratin with drug-containing new keratin growth; premature discontinuation leads to relapse. For tinea capitis caused by T. tonsurans, terbinafine has demonstrated superior mycological cure rates in comparative trials and is now preferred in many centers, particularly in adults and older children, while griseofulvin remains an acceptable first-line option for Microsporum canis-caused tinea capitis, where terbinafine has lower efficacy. Griseofulvin is no longer preferred for onychomycosis because of low cure rates and the requirement for very long treatment courses (12 to 18 months).89
Mechanism: tubulin binding → mitotic spindle disruption. Spectrum: dermatophytes only; no Candida, Aspergillus, Cryptococcus activity. Indications: tinea capitis (especially Microsporum); consider for Trichophyton tinea capitis if terbinafine not available. Duration: minimum 6–8 weeks (tinea capitis); onychomycosis no longer preferred. Fat with meals essential for microsize absorption. CYP3A4 inducer: OC failure risk; use barrier contraception. Contraindicated: pregnancy, hepatocellular failure, porphyria.
The three agents covered in this module occupy narrow but distinct clinical niches. Terbinafine is the preferred systemic antifungal for dermatophyte disease. Flucytosine has no role as monotherapy but is an essential partner in combination regimens for cryptococcal meningitis and selected severe Candida infections. Griseofulvin retains utility in tinea capitis in pediatric practice. Correct use requires accurate species identification, attention to drug-drug interactions, and appropriate monitoring protocols.
Dermatophyte Infections: Terbinafine vs. Griseofulvin. For onychomycosis caused by dermatophytes, oral terbinafine is the preferred agent based on superior mycological cure rates (approximately 70 to 80% vs. 30 to 40% for griseofulvin) and shorter treatment duration (12 weeks for toenails vs. up to 18 months for griseofulvin). Before starting therapy, nail sampling for fungal culture or polymerase chain reaction (PCR) testing is recommended to confirm dermatophyte etiology and exclude non-dermatophyte molds or Candida, for which terbinafine is poorly active. For tinea capitis, the choice between terbinafine and griseofulvin depends on the likely causative species: terbinafine is preferred for T. tonsurans and T. violaceum, while griseofulvin may be preferred for Microsporum canis, though this distinction is increasingly center-specific as terbinafine use has expanded. Topical treatment alone is insufficient for tinea capitis given its hair follicle involvement; systemic therapy is always required.39
Flucytosine in Cryptococcal Meningitis. The treatment of cryptococcal meningitis follows a three-phase strategy: induction (to achieve CSF sterilization), consolidation (to eliminate residual infection), and maintenance (to prevent relapse in immunocompromised patients). In the induction phase, flucytosine's role is as a partner to amphotericin B (preferred) or fluconazole (alternative). The choice between these partners is governed by drug availability, patient renal function, and the clinical setting. In patients with acute kidney injury (AKI) at presentation, beginning flucytosine alongside amphotericin B requires careful management because amphotericin-induced nephrotoxicity further reduces flucytosine clearance; in this scenario, TDM (therapeutic drug monitoring)-guided dosing rather than fixed renal-function-based tables provides the most reliable approach to maintaining safe flucytosine concentrations. Where neither amphotericin B nor flucytosine is available, high-dose fluconazole monotherapy is the only remaining option, though outcomes are inferior.610
Flucytosine in Candida Infections. Beyond cryptococcal meningitis, flucytosine has a secondary role as an adjunct in Candida infections that are difficult to eradicate with standard agents alone. These include Candida meningitis, endophthalmitis, and osteomyelitis, where standard agents alone may achieve inadequate tissue concentrations or where fungal burden is high. In Candida meningitis or shunt infections, flucytosine (combined with fluconazole) penetrates the CSF effectively and adds antifungal activity. In endophthalmitis, where vitreal penetration of many antifungals is limited, flucytosine's excellent tissue distribution is advantageous. These uses are outside the primary licensed indication and require specialist guidance, careful susceptibility testing, and TDM.10
Special Populations and Shared Considerations. In pediatric patients, terbinafine is now preferred over griseofulvin for most tinea capitis in many guidelines, but griseofulvin remains a well-studied option with decades of pediatric safety data. Terbinafine dosing in children is weight-based: below 20 kg use 62.5 mg once daily, 20 to 40 kg use 125 mg once daily, above 40 kg use 250 mg once daily, for the same durations as adults. In pregnancy, none of the three agents in this module is recommended: terbinafine has limited human safety data and is generally avoided in the first trimester; flucytosine is teratogenic in animal studies; griseofulvin is contraindicated. For immunocompromised patients receiving flucytosine, the risk of myelosuppression is heightened by concurrent cytotoxic drugs or other myelosuppressants, requiring more frequent CBC (complete blood count) monitoring. The interaction between flucytosine and amphotericin B on renal function is the single most important pharmacokinetic interaction to manage during combination induction therapy for cryptococcal meningitis.510
Terbinafine: squalene epoxidase inhibitor; fungicidal vs. dermatophytes; preferred for onychomycosis (12 weeks toenails) and tinea capitis (T. tonsurans); potent CYP2D6 inhibitor; monitor LFTs in at-risk patients; reduce dose for CrCl below 50 mL/min. Flucytosine: pyrimidine antimetabolite; never monotherapy; essential partner in AmB+5-FC induction for cryptococcal meningitis; TDM mandatory (target peak 25–50 mg/L, toxic above 100 mg/L); renal dose adjustment required; monitor CBC. Griseofulvin: microtubule inhibitor; spectrum limited to dermatophytes; tinea capitis principal indication; CYP3A4 inducer (OC failure); teratogenic; fat with meals required for absorption.
Ryder NS. The mechanism of action of terbinafine. Clin Exp Dermatol. 1989;14(2):98-100.
doi:10.1111/j.1365-2230.1989.tb00900.xBalfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs. 1992;43(2):259-284.
doi:10.2165/00003495-199243020-00010Gupta AK, Chow M, Daniel CR, et al. Treatments of tinea pedis. Dermatol Clin. 2003;21(3):431-462.
doi:10.1016/S0733-8635(03)00032-9Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171-179.
doi:10.1093/jac/46.2.171Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24-34.
doi:10.1128/AAC.00705-08Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004-1017.
doi:10.1056/NEJMoa1710922World Health Organization. Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV. Geneva: WHO; 2022. ISBN 9789240052178.
who.int/publications/i/item/9789240052178Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166(5-6):353-367.
doi:10.1007/s11046-008-9109-0Elewski BE, Caceres HW, DeLeon L, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol. 2008;59(1):41-54.
doi:10.1016/j.jaad.2008.02.019Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322.
doi:10.1086/649858